Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Geneticand Epigenetic Liability Testing Connects Facial and EmotionalRecognition Systems to Spectrum Disorders, Schizophrenia, Depression,and Anxiety

Our PGx-based GWAS meta-meta-analyses, coupled with genetic and epigenetic liability testing, connected Facial and Emotional Recognition Systems to Spectrum Disorders (Attention-Deficit Hyperactivity Disorder: ADHD and Autism), Schizophrenia, Depression, and Anxiety. We propose that these findings could have heuristic therapeutic targeting potential and, as such, require intensive further clinical support.